Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Stenham Asset Management. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD-3.3%
YTD+12.3%
Positioning StanceCONSTRUCTIVE
Market CapLarge Cap
GeographyUS, Global
Digest Analysis
Quick Take
"Stenham Equity UCITS Fund navigated a challenging Q2 2024 down 3.3% as narrow market breadth favored momentum over fundamental factors."
Executive Summary
Stenham Equity UCITS Fund declined 3.3% in Q2 2024, trailing the MSCI World Index's +2.2% return, while maintaining a YTD return of +12.3%. Relative performance was negatively impacted by historical lows in market breadth and record concentration in US large-cap technology equities (the Magnificent 7), alongside momentum factors outperforming fundamental quality factors. Short-term market dynamics, exacerbated by multi-manager platform hedge funds and quantitative strategies with shrinking holding periods, led to sharp stock price dislocations detached from business fundamentals. Stenham capitalized on this short-term volatility by expanding positions in long-term high-conviction holdings including ASML, Adyen, and Airbus following earnings-related drawdowns. Despite valuation multiple compression across the portfolio during the quarter, weighted average earnings estimates grew by 4%, reinforcing management's confidence in fundamental business strength. The portfolio remains strategically focused on long-term secular growth themes such as Aerospace, Payments, Life Sciences Equipment, and Railroads.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
80%
CautiousHigh
High Conviction (80%)
Assigned 0.80 reflecting high conviction. The portfolio holds sized positions (e.g., Airbus at 6.2%, LVMH at 6.2%) and management explicitly stepped up position sizes during price pullbacks on specific thesis points.
Growth Outlook
50%
BearishBullish
Neutral (50%)
Assigned 0.50 reflecting a balanced view: cautious/neutral on broader equity market technicals and concentration, but constructive on individual portfolio stock fundamentals.
Risk Appetite
75%
DefensiveAggressive
Aggressive (75%)
Assigned 0.75 as the manager remains net long and risk-on, actively leaning into market pullbacks in major holdings rather than raising cash or hedging.
Capital Deployment
75%
De-riskingDeploying
Deploying (75%)
Assigned 0.75 as the manager actively deployed capital into high-conviction positions (ASML, Adyen, Airbus) on share price weakness caused by quarterly earnings events, demonstrating clear net buy activity.
Forward Guidance
75%
CautiousExpansionary
Expansionary (75%)
Assigned 0.75 because management clearly outlines a forward strategy of continuing to buy dislocated, high-quality companies when short-term earnings volatility causes market overreactions.
Language Signal
65%
BearishBullish
Bullish (65%)
Assigned 0.65 due to constructive tone regarding fundamental earnings growth (+4%) and attractive buying opportunities, balanced by explicit discussion of narrow market breadth and relative headwinds.
Perceived Risk
65%
Low RiskElevated
Elevated Risk (65%)
Assigned 0.65 due to explicit detail surrounding market structure risks, including multi-manager platform leverage, historically narrow market breadth, and shrinking investor time horizons.
Opportunity Density
75%
ScarceAbundant
Abundant (75%)
Assigned 0.75 as the manager sees a rich opportunity set created by short-term market dislocations and overreactions in quality compounders.
Time Horizon
85%
Short-TermLong-Term
Decade+ (85%)
Assigned 0.85 reflecting an explicit multi-year to decade-long investment horizon, contrasting their patient compounding approach against the market's 5.5-month average holding period.